Researchers have highlighted the role of circular RNA circLIMK1-005 in promoting lung adenocarcinoma progression via interaction with the RPA1-CDK4 pathway, offering a promising molecular target. Separately, advances in engineering breast cancer cells to enhance immunogenicity provide a novel approach to tumor vaccine development. Additionally, small-molecule tyrosine kinase inhibitors (TKIs) have demonstrated improved efficacy profiles in treating HER2-positive breast cancer in neoadjuvant settings. Together, these studies contribute to evolving strategies for aggressive breast cancer subtypes, including triple-negative breast cancer, with a focus on tailored therapeutics.